Bharat Biotech had submitted application for Emergency Use Listing back on April 19, providing all necessary information including the results of the Phase 3 clinical trials in which it demonstrated 77.8 per cent efficacy and further provided 65.2% protection against the new Delta variant., Bharat Biotech had submitted application for Emergency Use Listing back on April 19, providing all necessary information including the results of the Phase 3 clinical trials in which it demonstrated 77.8 per cent efficacy and further provided 65.2% protection against the new Delta variant., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way